Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953235 · ClinicalTrials.gov registry record · Phase 1
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
A Phase 1 study, sponsored by Gritstone bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT03953235: Completed Phase 1 study, sponsored by Gritstone bio.
NCT03953235 is a Phase 1 study that has completed, run by Gritstone bio. The registered enrollment target is 39 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03953235, a Phase 1 study, has completed, sponsored by Gritstone bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in patients with advanced or metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. Based on the Phase 1 data, an updated vaccine candidate (SLATE-KRAS or version 2) was developed that removed 16 of the 20 mutations included in the original vaccine (version 1) and solely targets KRAS mutations.
Interventions
- BIOLOGICAL nivolumab
- BIOLOGICAL ipilimumab
- BIOLOGICAL GRT-C903
- BIOLOGICAL GRT-R904
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2019-07-18 |
| Est. Completion | 2023-03-10 |
| Phase | Phase 1 |
What the finished NCT03953235 record still lists
NCT03953235 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 4 interventions - of which nivolumab is the first listed.
NCT03953235 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03953235 about?
NCT03953235 is a clinical study titled "A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens". The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in patients with advanced or metastatic non-small cell lung cancer, microsate...
What is the current status of trial NCT03953235?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2019-07-18. Estimated completion is 2023-03-10.
What interventions are being tested in trial NCT03953235?
The interventions under investigation include: nivolumab (BIOLOGICAL), ipilimumab (BIOLOGICAL), GRT-C903 (BIOLOGICAL), GRT-R904 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03953235?
This trial is sponsored by Gritstone bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03953235's enrollment target sits among peer trials
39 1191st of 2000 higher than 804 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI